| Dr Christopher Mueller, MD | |
|
2000 S Thompson St, Flagstaff, AZ 86001-8759 | |
| (928) 226-6400 | |
| Not Available |
| Full Name | Dr Christopher Mueller |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 15 Years |
| Location | 2000 S Thompson St, Flagstaff, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295977718 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Flagstaff Medical Center | Flagstaff, AZ | Hospital |
| St Josephs Community Hospital West Bend | West bend, WI | Hospital |
| Verde Valley Medical Center | Cottonwood, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northern Arizona Healthcare Corporation | 3577473362 | 370 |
News Archive
Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.
The National Institutes of Health (NIH) today announced a new clinical research program that will aim to provide answers to patients with mysterious conditions that have long eluded diagnosis. Called the Undiagnosed Diseases Program, the trans-NIH initiative will focus on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, Md., by physicians across the nation.
Over the last 15 years, researchers have found a significant association between vascular diseases such as hypertension, atherosclerosis, diabetes type 2, hyperlipidemia, and heart disease and an increased risk of Alzheimer's disease.
ASTRO President Anthony Zietman, M.D., spoke before the Medicare Evidence Development and Coverage Advisory Committee meeting today on radiation therapy for treatment of localized prostate cancer. MEDCAC provides advice and recommendations to the Centers for Medicare and Medicaid Services for what is covered by Medicare and Medicaid, based on scientific evidence.
› Verified 2 days ago
| Entity Name | Northern Arizona Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669914552 PECOS PAC ID: 3577473362 Enrollment ID: O20170801003409 |
News Archive
Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.
The National Institutes of Health (NIH) today announced a new clinical research program that will aim to provide answers to patients with mysterious conditions that have long eluded diagnosis. Called the Undiagnosed Diseases Program, the trans-NIH initiative will focus on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, Md., by physicians across the nation.
Over the last 15 years, researchers have found a significant association between vascular diseases such as hypertension, atherosclerosis, diabetes type 2, hyperlipidemia, and heart disease and an increased risk of Alzheimer's disease.
ASTRO President Anthony Zietman, M.D., spoke before the Medicare Evidence Development and Coverage Advisory Committee meeting today on radiation therapy for treatment of localized prostate cancer. MEDCAC provides advice and recommendations to the Centers for Medicare and Medicaid Services for what is covered by Medicare and Medicaid, based on scientific evidence.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Mueller, MD 1200 N Beaver St, Attn: Payer Credentialing, Flagstaff, AZ 86001-3118 Ph: (928) 213-6235 | Dr Christopher Mueller, MD 2000 S Thompson St, Flagstaff, AZ 86001-8759 Ph: (928) 226-6400 |
News Archive
Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.
The National Institutes of Health (NIH) today announced a new clinical research program that will aim to provide answers to patients with mysterious conditions that have long eluded diagnosis. Called the Undiagnosed Diseases Program, the trans-NIH initiative will focus on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, Md., by physicians across the nation.
Over the last 15 years, researchers have found a significant association between vascular diseases such as hypertension, atherosclerosis, diabetes type 2, hyperlipidemia, and heart disease and an increased risk of Alzheimer's disease.
ASTRO President Anthony Zietman, M.D., spoke before the Medicare Evidence Development and Coverage Advisory Committee meeting today on radiation therapy for treatment of localized prostate cancer. MEDCAC provides advice and recommendations to the Centers for Medicare and Medicaid Services for what is covered by Medicare and Medicaid, based on scientific evidence.
› Verified 2 days ago
Christopher H Murphy, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 N Beaver St, Flagstaff, AZ 86001 Phone: 928-773-0003 Fax: 928-773-1170 | |
Craig Michael Peters, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1215 N Beaver St, Heart & Vascular Center Of Northern Arizona, Flagstaff, AZ 86001 Phone: 928-773-2200 Fax: 928-773-2201 | |
Dr. James Malcolm Galloway, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1215 N Beaver St, Suite 201, Flagstaff, AZ 86001 Phone: 028-214-3920 Fax: 928-214-3924 | |
Joseph Anthony Scionti, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 N Beaver St, Flagstaff, AZ 86001 Phone: 928-214-2920 Fax: 928-214-2925 | |
Mr. Matthew Ian Gembala, M.D., M.P.H. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2201 N Vickey St Ste 110, Flagstaff, AZ 86004 Phone: 928-213-9460 Fax: 928-213-9465 | |
Dr. Christina Veenstra, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 N Beaver St, Flagstaff, AZ 86001 Phone: 928-773-2451 Fax: 928-214-2925 | |
Dr. Kyle Collingwood Edwards, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 N Beaver St, Flagstaff, AZ 86001 Phone: 928-773-2451 Fax: 928-214-2925 |